UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
 

FORM 15
 
 
CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION
UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934
OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934.
 
Commission File Number: 333-196065
 

Parnell Pharmaceuticals Holdings Ltd
(Exact name of registrant as specified in its charter)
 
Unit 4, Century Estate. 476 Gardeners Road. Alexandria 2015 NSW, Australia, 1800 665 882
(Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

 Ordinary Shares, no par value
(Title of each class of securities covered by this Form)

None
(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)
 

 
Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:
 
 
     Rule 12g-4(a)(1)
☒
   
 
     Rule 12g-4(a)(2)
☐
   
 
     Rule 12h-3(b)(1)(i)
☒
   
 
     Rule 12h-3(b)(1)(ii)
☐
   
 
     Rule 15d-6
☐
   
 
     Rule 15d-22(b)
☐
   
 
Approximate number of holders of record as of the certification or notice date:  37
 
Pursuant to the requirements of the Securities Exchange Act of 1934, Parnell Pharmaceuticals Holdings Ltd has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

       January 3, 2017                               By /s/ Brad McCarthy                              Director and Chief Financial Officer
Date                                                      Name                                                                 Title
 


Parnell Pharmaceuticals (CE) (USOTC:PARNF)
過去 株価チャート
から 10 2024 まで 11 2024 Parnell Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック
Parnell Pharmaceuticals (CE) (USOTC:PARNF)
過去 株価チャート
から 11 2023 まで 11 2024 Parnell Pharmaceuticals (CE)のチャートをもっと見るにはこちらをクリック